{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:38:04Z","timestamp":1758634684981},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.transproceed.2018.03.028","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T19:47:41Z","timestamp":1521143261000},"page":"1904-1909","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety of Mammalian Target of Rapamycin Inhibitor Use\u2014Long-term Follow-up of First Tuberous Sclerosis Complex Patient Treated De Novo With Sirolimus After Kidney Transplantation: A Case Report"],"prefix":"10.1016","volume":"50","author":[{"given":"A.","family":"Tarasewicz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"D\u0119bska-\u015alizie\u0144","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Rutkowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Szurowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Matuszewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2018.03.028_bib1","doi-asserted-by":"crossref","first-page":"9820181","DOI":"10.1155\/2017\/9820181","article-title":"Recent advances and challenges of mTOR inhibitors use in the treatment of patients with tuberous sclerosis complex","volume":"2017","author":"Palavra","year":"2017","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.transproceed.2018.03.028_bib2","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.transproceed.2018.03.028_bib3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.transproceed.2018.03.028_bib4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ceb.2017.02.012","article-title":"mTORC1 signaling and the metabolic control of cell growth","volume":"45","author":"Ben-Sahra","year":"2017","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.transproceed.2018.03.028_bib5","doi-asserted-by":"crossref","first-page":"13571","DOI":"10.1073\/pnas.202476899","article-title":"Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling","volume":"99","author":"Tee","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.transproceed.2018.03.028_bib6","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2133.2008.08677.x","article-title":"The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis","volume":"159","author":"Hofbauer","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.transproceed.2018.03.028_bib7","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1016\/j.transproceed.2009.06.227","article-title":"Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex","volume":"41","author":"Tarasewicz","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2018.03.028_bib8","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1432-2277.2009.01041.x","article-title":"Sirolimus in renal transplant recipients with tuberous sclerosis complex: clinical effectiveness and implications for innate immunity","volume":"230","author":"Haidinger","year":"2010","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2018.03.028_bib9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.trre.2010.11.001","article-title":"Targeting the dysregulated mammalian target of rapamycin pathway in organ transplantation: killing 2 birds with 1 stone","volume":"25","author":"Haidinger","year":"2011","journal-title":"Transplant Rev"},{"key":"10.1016\/j.transproceed.2018.03.028_bib10","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1093\/ndt\/gfm552","article-title":"Combined nephrectomy and pre-emptive renal transplantation in a tuberous sclerosis patient with angiomyolipoma, renal carcinoma and lifethreatening abdominal haemorrhages","volume":"22","author":"Corsenca","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2018.03.028_bib11","first-page":"397087","article-title":"Tuberous sclerosis associated with polycystic kidney disease: effects of rapamycin after renal transplantation","author":"Rosado","year":"2013","journal-title":"Case Rep Transplant"},{"key":"10.1016\/j.transproceed.2018.03.028_bib12","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1016\/j.transproceed.2014.09.065","article-title":"Everolimus in immunosuppressive treatment after kidney transplantation in a patient with tuberous sclerosis: case report","volume":"46","author":"Tarasewicz","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2018.03.028_bib13","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.pediatrneurol.2015.01.004","article-title":"Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex","volume":"52","author":"Goyer","year":"2015","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.transproceed.2018.03.028_bib14","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/uog.13434","article-title":"Prenatal diagnosis of giant cardiac rhabdomyoma in tuberous sclerosis complex: a new therapeutic option with everolimus","volume":"45","author":"Mlczoch","year":"2015","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.transproceed.2018.03.028_bib15","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1542\/peds.2012-3607","article-title":"Possible prevention of tuberous sclerosis complex lesions","volume":"132","author":"Kotulska","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.transproceed.2018.03.028_bib16","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.drudis.2015.05.006","article-title":"Sirolimus and everolimus in kidney transplantation","volume":"20","author":"Moes","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.transproceed.2018.03.028_bib17","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jcph.428","article-title":"Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation","volume":"55","author":"Somers","year":"2015","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.transproceed.2018.03.028_bib18","doi-asserted-by":"crossref","first-page":"E625","DOI":"10.1111\/ctr.12223","article-title":"Wound events in kidney transplant patients receiving de novo everolimus: a pooled analysis of three randomized controlled trials","volume":"27","author":"Cooper","year":"2013","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2018.03.028_bib19","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/neuonc\/nov152","article-title":"Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex","volume":"17","author":"MacKeigan","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.transproceed.2018.03.028_bib20","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.pharep.2016.01.005","article-title":"Management of side effects of mTOR inhibitors in tuberous sclerosis patients","volume":"68","author":"Sadowski","year":"2016","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.transproceed.2018.03.028_bib21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.transproceed.2018.03.028_bib22","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.transproceed.2018.03.028_bib23","doi-asserted-by":"crossref","first-page":"e0158476","DOI":"10.1371\/journal.pone.0158476","article-title":"Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study","volume":"11","author":"Franz","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.transproceed.2018.03.028_bib24","doi-asserted-by":"crossref","first-page":"e0180939","DOI":"10.1371\/journal.pone.0180939","article-title":"Everolimus long-term use in patients with tuberous sclerosis complex: four-year update of the EXIST-2 study","volume":"12","author":"Bissler","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.transproceed.2018.03.028_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13023-017-0581-9","article-title":"Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide","volume":"12","author":"Davies","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.transproceed.2018.03.028_bib26","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jaad.2015.07.018","article-title":"Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus","volume":"73","author":"Nathan","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.transproceed.2018.03.028_bib27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jamadermatol.2016.3545","article-title":"Efficacy and safety of topical sirolimus therapy for facial angiofibromas in the tuberous sclerosis complex: a randomized clinical trial","volume":"153","author":"Wataya-Kaneda","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.transproceed.2018.03.028_bib28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ccm.2016.04.002","article-title":"Lymphangioleiomyomatosis","volume":"37","author":"Johnson","year":"2016","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.transproceed.2018.03.028_bib29","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2018.03.028_bib30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.chest.2017.05.012","article-title":"Long-term effect of sirolimus on serum vascular endothelial growth factor D levels in patients with lymphangioleiomyomatosis","volume":"153","author":"Taveira-DaSilva","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.transproceed.2018.03.028_bib31","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1164\/rccm.201405-0918OC","article-title":"Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis","volume":"190","author":"Yao","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.transproceed.2018.03.028_bib32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1750-1172-7-87","article-title":"Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial","volume":"7","author":"Cabrera-Lopez","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.transproceed.2018.03.028_bib33","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","article-title":"Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial","volume":"17","author":"Davies","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.transproceed.2018.03.028_bib34","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2018.03.028_bib35","doi-asserted-by":"crossref","first-page":"e23379","DOI":"10.1371\/journal.pone.0023379","article-title":"Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and VEGF-D levels decrease","volume":"6","author":"Dabora","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.transproceed.2018.03.028_bib36","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/jdv.13356","article-title":"Systemic effects of treatment with mTOR inhibitors in tuberous sclerosis complex: a comprehensive review","volume":"30","author":"Sadowski","year":"2016","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.transproceed.2018.03.028_bib37","first-page":"1424","article-title":"Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a systematic review","volume":"192","author":"Peng","year":"2014","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.transproceed.2018.03.028_bib38","doi-asserted-by":"crossref","first-page":"e26347","DOI":"10.1002\/pbc.26347","article-title":"Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study)","volume":"64","author":"Treli\u0144ska","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.transproceed.2018.03.028_bib39","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/1756287216641353","article-title":"Optimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic review","volume":"8","author":"Bissler","year":"2016","journal-title":"Ther Adv Urol"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134518303506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134518303506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T03:18:30Z","timestamp":1532661510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134518303506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0041134518303506"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2018.03.028","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Mammalian Target of Rapamycin Inhibitor Use\u2014Long-term Follow-up of First Tuberous Sclerosis Complex Patient Treated De Novo With Sirolimus After Kidney Transplantation: A Case Report","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2018.03.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}